Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Will Use Accelrys Software to Speed Drug Discovery

NEW YORK, Jan. 29 - Accelrys has struck a global licensing agreement with AstraZeneca, the informatics firm said on Tuesday.

 

Terms of the deal call for AstraZeneca researchers to use Accelrys software to understand therapeutic target and to identify and optimize lead compounds, said Accelrys, a Pharmacopeia unit.

 

Financial details of the agreement were not disclosed.

 

The arrangement covers scientists at 10 research sites worldwide, including Montreal; Bangalore, India; Södertalje, Lund, and Mölndal, in Sweden; and Wilmington, Del., and Boston, in the US.

 

All researchers will have access to Accelrys software libraries for modeling and simulation.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.